Further work should also aim to increase the proteoform resolution of this assay, particularly for phosphorylated [28–30] and differentially cleaved [29, 31–33] tau proteoforms that are emerging as diagnostic biomarkers for Alzheimer’s Disease and new targets for next-generation tau immunotherapies. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.